After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also developing newer medicines that will improve its financial results. 10 stocks we ...

With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is initiating a Phase 2 study ...

It's full steam ahead for a new Regeneron facility in Saratoga Springs. The company has learned that Saratoga County's ...

Following FDA rejections, Regeneron and Scholar Rock are turning to other facilities to clear regulatory logjams created by ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Regeneron released new early data on two of its blood cancer drugs at ASH, aiming to expand treatment options for patients ...

The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company’s deep pipeline Monday at the J.P. Morgan Healthcare Conference, CEO Len ...

The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a ...